Although the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions in PIK3CA mutant xenografts, the molecular mechanism underlying the resistance of AKTi and the synergy seen on the PI3K inhibitors and CDK4/6 inhibitors remain elusive. Here, CDK4 is linked to neoplasm.